Phuturdex › Diseases › Dementia
Drugs in development · updated 30 October 2026
Dementia: drugs in development
As of 30 October 2026 there are 52 active clinical trials (recruiting or ongoing, phases I–III) on 54 drugs for dementia. 33 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| E2814 | II–III | 2 | NCT05269394 |
| Remternetug | II–III | 2 | NCT05552157 |
| [18F]-APN-1607 | III | 1 | NCT07422857 |
| Gantenerumab | II–III | 1 | NCT01760005 |
| MazdutideIBI362, LY3305677 | III | 1 | NCT07083154 |
| RG6289 | II–III | 1 | NCT06996730 |
| Solanezumab | II–III | 1 | NCT01760005 |
| Xanamem | II–III | 1 | NCT06125951 |
| 18F-Florbetaben | II | 2 | NCT07758660 |
| ML-007C-MA | II | 2 | NCT06887192 |
| 18F-MK6240 | II | 1 | NCT07758660 |
| [18F]RP-115 | I–II | 1 | NCT05374278 |
| AADvac1 | II | 1 | NCT06957418 |
| ACI-24.060 | I–II | 1 | NCT05462106 |
| AGB101 | II | 1 | NCT06919926 |
| ALN-6457 | I–II | 1 | NCT07832370 |
| Ambroxol Hydrochloride | I–II | 1 | NCT04405596 |
| BMS-986446 | II | 1 | NCT06268886 |
| CORT108297 | II | 1 | NCT04601038 |
| GSK4527226 | II | 1 | NCT07105709 |
| N-acetylcysteine amideNACA | II | 1 | NCT07716865 |
| NBI-1117567 | II | 1 | NCT07832383 |
| Nicorandil Oral Tablet | II | 1 | NCT04120766 |
| NPI-001 | II | 1 | NCT07741526 |
| S-equolEquol | II | 1 | NCT05741060 |
| SPG302 | II | 1 | NCT06427668 |
| VHB937 | II | 1 | NCT07094516 |
| 11C-MC1 | I | 1 | NCT04396873 |
| 11C-PS13 | I | 1 | NCT04396873 |
| ALN-5288 | I | 1 | NCT07214727 |
| LY3439539 | I | 1 | NCT07598370 |
| LY3954068 | I | 1 | NCT06297590 |
| NIO752 | I | 1 | NCT05469360 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DonanemabKisunla® | II–III | 5 | NCT06996730 |
| LecanemabLeqembi Iqlik®, Leqembi® | II–III | 3 | NCT05269394 |
| AtorvastatinLipitor, Atorvaliq® | III | 1 | NCT07012629 |
| ClopidogrelClopidgrel, Clopidogrel Zentiva (previously Clopidogrel Winthrop)® | III | 1 | NCT07012629 |
| DexamethasoneDexametasone, Dextenza | III | 1 | NCT05738486 |
| EscitalopramLexapro | III | 1 | NCT03108846 |
| LevetiracetamSpritam®, Elepsia Xr® | III | 1 | NCT07234695 |
| MetforminRiomet Er®, Glumetza® | III | 1 | NCT04511416 |
| RosuvastatinEzallor Sprinkle®, Crestor® | III | 1 | NCT07012629 |
| Tranexamic AcidTransexamic acid, Lysteda® | III | 1 | NCT05470816 |
| 18F-AV-1451[18F] Flortaucipir, Flortaucipir F18 | II | 2 | NCT06723015 |
| AmlodipineSdamlo®, Norliqva® | II | 1 | NCT05331144 |
| DeferiproneFerriprox®, Deferiprone Lipomed® | I–II | 1 | NCT03754725 |
| LemborexantDayvigo® | II | 1 | NCT06823752 |
| LosartanArbli®, Cozaar® | II | 1 | NCT05331144 |
Sorted by most advanced phase and number of active trials. Showing 15 of 21 drugs.
All 54 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Alzheimer's disease 157 drugs
- Cognitive dysfunction 94 drugs
- Huntington's disease 14 drugs
- Frontotemporal dementia 11 drugs
- Amyloid 9 drugs
- Lewy body dementia 7 drugs
- Parkinson's disease 104 drugs
- Neurodegenerative Diseases 25 drugs
- Inflammation 85 drugs
- Down syndrome 36 drugs
- Psychomotor agitation 10 drugs
- Tauopathies 10 drugs
Broader categories
- Mental disorder 24 drugs
- Neurocognitive Disorders 10 drugs
- Nervous System Diseases 39 drugs
- Brain Diseases 23 drugs
- Central nervous system disease 38 drugs
- Tauopathies 10 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003704 “Dementia”.